Table 1.
Serological analysis of the study population according to the clinical outcome in subjects screened once (Table 1A) and twice (Table 1B)
| Severe cases (H) | Pauci‐symptomatic (P) | |
|---|---|---|
| Table 1A | T0 (30) | T0 (30) |
| CMIA IgG (S/SCO) | 6.21 (5.47–6.95) | 4.95 (3.97–5.93) |
| ELISA IgG (AU) | 7.31 (5.82–8.80) | 4.06 (2.81–5.31) |
| NT Ab (GMT) | 87.7 (54.9–121.0) | 23.3 (10.4–36.2) |
| Severe cases (H) | Pauci‐symptomatic (P) | |||
|---|---|---|---|---|
| Table 1B | T0 (10) | T1 (10) | T0 (10) | T1 (10) |
| CMIA IgG (S/SCO) | 5.63 (4.06–7.22) | 5.54 (4.19–6.89) | 6.46 (5.23–7.69) | 4.94 (3.61–6.27) |
| ELISA IgG (AU) | 6.16 (3.31–9.01) | 6.28 (3.68–8.88) | 5.01 (2.49–7.53) | 3.23 (2.01–4.45) |
| NT Ab (GMT) | 65.38 (0–254.0) | 100.51 (14.6–186.0) | 29.21 (8.61–49.8) | 21.52 (0–45.4) |
Note: 95% CI values were indicated below each result.
Abbreviations: AU, arbitrary units; CI, confidence interval; GMT, geometric mean titer; S/SCO, signal/signal cut off.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.